MetaCore PKU, the company’s medical nutrition product designed to support the dietary management of phenylketonuria, has been adopted by a growing number of UK specialist metabolic centres following its 2023 launch and 2024 NHS framework inclusion.
The product is commercialised in the United Kingdom for use under the supervision of healthcare professionals. Adoption has been driven by specialist clinical teams seeking differentiated medical nutrition options for adolescent and adult patients.
Use and supervision
MetaCore PKU is a medical nutrition product for the dietary management of phenylketonuria. It is intended for use under the supervision of a registered metabolic dietitian or healthcare professional.
“Differentiated medical nutrition options matter to the metabolic community. We are pleased to support specialist centres with practical products that fit existing dietary regimens.”
MetaCore PKU is a medical nutrition product. Use should be supervised by a registered metabolic dietitian or healthcare professional. Availability varies by territory.